| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
94,090 |
39,702 |
$3.03M |
| 87632 |
|
31,516 |
18,460 |
$2.57M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
38,354 |
17,681 |
$2.55M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
60,983 |
31,486 |
$1.59M |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
43,559 |
17,977 |
$876K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
29,893 |
15,848 |
$499K |
| 87486 |
|
28,648 |
16,179 |
$499K |
| 87581 |
|
28,492 |
16,039 |
$489K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
20,619 |
9,709 |
$374K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
52,580 |
16,489 |
$303K |
| 87631 |
|
1,783 |
1,247 |
$41K |
| 87634 |
|
1,625 |
1,131 |
$40K |
| 87428 |
|
86 |
79 |
$5K |
| 86769 |
|
34 |
28 |
$642.72 |
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
690 |
411 |
$359.64 |
| 86408 |
|
13 |
13 |
$252.78 |
| 86328 |
|
15 |
15 |
$180.92 |